6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome

6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome

Quick Answer: Cannabis exerts its psychoactive effects via $\Delta^9$-tetrahydrocannabinol ($\Delta^9$-THC), a partial agonist at presynaptic $CB_1$ receptors that inhibit GABA and glutamate release. DSM-5-TR Cannabis Withdrawal Syndrome (CWS) develops within 24–72 hours of stopping prolonged daily use, characterized by $\ge 3$ symptoms (irritability, anxiety, insomnia/vivid dreams, anorexia, restlessness, depressed mood, physical chills/headaches/pain) peaking at days 2–6. In chronic daily users ($>1$ year), Cannabinoid Hyperemesis Syndrome (CHS) can emerge as a paradoxical condition marked by intractable retching, abdominal pain, and pathognomonic compulsive hot bathing (which restores hypothalamic thermoregulation and activates TRPV1 vanilloid receptors). Conventional antiemetics like ondansetron are notoriously ineffective. Acute first-line management requires topical capsaicin cream (0.025%–0.075%), low-dose IV haloperidol (0.5–2 mg), and aggressive IV volume resuscitation, while complete, sustained cannabis abstinence is the only definitive cure. Investigational pharmacotherapies for CUD include N-Acetylcysteine (NAC 1,200 mg BID) in youth and Gabapentin for withdrawal insomnia.

---

1. Endocannabinoid Neurobiology & DSM-5-TR Cannabis Use Disorder

The endogenous cannabinoid system (ECS) is a complex retrograde neuromodulatory network that regulates neurotransmitter release, synaptic plasticity, pain perception, gastrointestinal motility, and emotional homeostasis.

Endocannabinoid Receptors & Retrograde Signaling

• Endogenous Ligands: The two primary endocannabinoids are arachidonic acid derivatives synthesized on-demand from membrane phospholipids: Anandamide (AEA) and 2-Arachidonoylglycerol (2-AG).
• Retrograde Synaptic Transmission: Unlike classical neurotransmitters stored in presynaptic vesicles, endocannabinoids are synthesized in the post-synaptic dendritic spine in response to intracellular calcium influx. They travel retrogradely across the synaptic cleft to bind presynaptic Cannabinoid Receptor Type 1 ($CB_1$) and Type 2 ($CB_2$).
• $CB_1$ Receptors: Predominantly localized in the central nervous system on presynaptic axon terminals across the cerebral cortex, hippocampus, basal ganglia, cerebellum, and the ventral tegmental area. Coupling to inhibitory $G_{i/o}$ proteins, $CB_1$ activation closes voltage-gated $Ca^{2+}$ channels and opens inwardly rectifying $K^+$ channels, suppressing presynaptic neurotransmitter release (both inhibitory GABA and excitatory glutamate).
• Phytocannabinoids (Δ9-THC vs CBD):
  • $\Delta^9$-Tetrahydrocannabinol ($\Delta^9$-THC): The primary psychoactive constituent of cannabis; acts as a partial agonist at $CB_1$ and $CB_2$ receptors. Highly lipophilic, THC rapidly accumulates in adipose tissue and has an extended elimination terminal half-life of 5 to 13 days in chronic heavy users, with urinary metabolites (THC-COOH) detectable for 30 to 60+ days.
  • Cannabidiol (CBD): Non-intoxicating constituent that exhibits low affinity for $CB_1$ and acts as a negative allosteric modulator at $CB_1$ receptors, dampening THC-induced tachycardia, paranoia, and cognitive impairment while possessing independent anxiolytic, anti-inflammatory, and anticonvulsant properties.

[Post-Synaptic Depolarization & Ca²⁺ Influx]
                     │
                     ▼
[On-Demand Synthesis of AEA & 2-AG]
                     │
                     ▼ (Retrograde Diffusion across Cleft)
[Binds Presynaptic CB1 Receptors (Gi/o Coupled)]
                     │
                     ▼
[Blockade of Presynaptic Ca²⁺ Influx & Efflux of K⁺]
                     │
                     ▼
[Suppression of Presynaptic Neurotransmitter Release (GABA / Glutamate)]

DSM-5-TR Diagnostic Criteria for Cannabis Use Disorder

Cannabis Use Disorder is diagnosed when an individual exhibits a problematic pattern of cannabis use leading to clinically significant impairment or distress, manifested by at least 2 of 11 criteria within a 12-month period across four core domains (Impaired Control, Social Impairment, Risky Use, Pharmacological Criteria: Tolerance and Withdrawal):

• Mild CUD: 2 to 3 criteria
• Moderate CUD: 4 to 5 criteria
• Severe CUD: 6 or more criteria

Cannabis Withdrawal Syndrome (CWS)

Cannabis Withdrawal Syndrome is officially recognized in DSM-5-TR. It occurs following cessation of heavy and prolonged cannabis use (typically daily or near-daily use for at least several months). Diagnosis requires the emergence of at least 3 of the following 7 symptoms within 24 to 72 hours of cessation:

1. Irritability, anger, or aggression
2. Nervousness or anxiety
3. Sleep difficulty (insomnia, vivid dreams, terrifying nightmares)
4. Decreased appetite or weight loss
5. Restlessness
6. Depressed mood
7. At least one significant physical symptom: Abdominal pain, shakiness/tremors, diaphoresis, fever, chills, or headache.

Time Post-Cannabis Cessation:
0h            24h–48h                     Day 2–6                    Day 14–30
├──────────────┼────────────────────────────┼───────────────────────────┤
               ▲                            ▲                           ▲
               │                            │                           │
               └─ Onset of CWS              └─ PEAK SEVERITY            └─ Resolution of Somatic Symptoms
                  (Anxiety, Anorexia,          (Intense Irritability,       (Sleep disruption & vivid dreams
                   Insomnia)                    Sweating, Tremors, Cravings) may persist for weeks/months)

• Clinical Trajectory: Symptoms begin within 24 to 48 hours of the last dose, reach peak intensity between Days 2 and 6, and typically persist for 1 to 2 weeks. However, sleep architecture disruptions (loss of slow-wave sleep, REM rebound causing disturbing dreams) frequently persist for several months.

---

2. Cannabinoid Hyperemesis Syndrome (CHS): Pathophysiology & The Paradox

First described by Allen and colleagues in 2004, Cannabinoid Hyperemesis Syndrome (CHS) is a severe clinical syndrome characterized by recurrent episodes of intractable nausea, cyclically debilitating vomiting, and colicky abdominal pain occurring in individuals with chronic, heavy, daily cannabis use ($>1$ year).

The Clinical Paradox: Why Does an Antiemetic Cause Hyperemesis?

Acute, low-dose THC stimulates $CB_1$ receptors in the dorsal vagal complex of the brainstem and the chemoreceptor trigger zone (CTZ), producing potent central antiemetic effects (the basis for synthetic THC analogs like dronabinol). However, chronic daily exposure to high-concentration cannabinoids triggers a profound paradoxical toxicity:

1. Enteric $CB_1$ Downregulation & Gastric Dysmotility: Sustained high-potency THC exposure causes down-regulation, desensitization, and internalization of $CB_1$ receptors in the enteric nervous system (Auerbach’s and Meissner’s plexuses). This suppresses vagal motor output, leading to profound gastric hypomotility, delayed gastric emptying (gastroparesis), and mesenteric vasodilation.
2. Hypothalamic-Vanilloid Disruption & TRPV1 Desensitization: Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective cation channel located in sensory nociceptors, enteric nerves, and the thermoregulatory center of the hypothalamus. Cannabinoids bind directly to and functionally downregulate/desensitize TRPV1. This causes a dual breakdown: peripheral visceral hyperalgesia (severe abdominal cramping) and central thermoregulatory hypothermia.
3. The Pathognomonic Compulsive Hot Bathing / Showering: Patients discover through trial and error that immersing themselves in scalding-hot water (often spending 4 to 12 hours a day in the shower) provides immediate, dramatic, albeit temporary relief from vomiting and abdominal agony. Scalding water stimulates peripheral cutaneous thermal receptors, sending signals that activate hypothalamic TRPV1 channels and restore thermoregulatory equilibrium while inducing cutaneous vasodilation that shifts blood flow away from congested splanchnic vascular beds.

[Chronic Daily High-THC Cannabis Exposure (>1 year)]
                         │
       ┌─────────────────┴─────────────────┐
       ▼                                   ▼
[Enteric CB1 Downregulation]       [Hypothalamic/Enteric TRPV1 Desensitization]
       │                                   │
       ▼                                   ▼
[Gastric Hypomotility,             [Central Thermoregulatory Instability &
 Delayed Gastric Emptying]          Visceral Splanchnic Hyperalgesia]
       │                                   │
       └─────────────────┬─────────────────┘
                         ▼
        [Intractable Cyclical Hyperemesis & Visceral Pain]
                         ▲
                         │ (Relieved temporarily by)
     [Compulsive Scalding Hot Showers / Bathing]
     (Thermal stimulation restores TRPV1 firing & hypothalamic balance)

---

3. The Three Clinical Phases of CHS

Cannabinoid Hyperemesis Syndrome unfolds across three distinct, predictable phases:

1. Prodromal Phase (Months to Years)

• Manifestations: Insidious early morning nausea, vague epigastric or periumbilical discomfort, anorexia, and a persistent fear of vomiting. Intestinal motility is sluggish.
• Diagnostic Pitfall: The patient typically maintains normal appetite throughout the remainder of the day and does not exhibit overt emesis. Crucially, the patient often escalates cannabis consumption, believing that marijuana is a natural herbal medicine that treats their nausea. Compulsive bathing has not yet fully developed.

2. Hyperemetic Phase (Days to Weeks)

• Manifestations: Sudden, paroxysmal onset of incapacitating, unrelenting vomiting and retching (often 20 to 30 episodes per day), accompanied by diffuse colicky abdominal pain, profound thirst, and diaphoresis.
• Compulsive Bathing Hallmark: Patients engage in obsessive, compulsive scalding-hot showering or bathing. If water temperature cools, vomiting immediately resumes.
• Life-Threatening Clinical Complications:
  • Severe Dehydration & Hypovolemic Shock
  • Prerenal Acute Kidney Injury (AKI): Profound elevations in BUN and serum creatinine due to severe volume depletion, potentially progressing to acute tubular necrosis (ATN).
  • Severe Electrolyte Collapse: Profound hypokalemia, hypochloremia, and metabolic alkalosis secondary to massive gastric hydrochloric acid ($HCl$) loss from recurrent emesis.
  • Esophageal Rupture & Trauma: Mallory-Weiss mucosal tears, Boerhaave syndrome, and pneumomediastinum.
  • Rhabdomyolysis: Driven by prolonged retching, muscular straining, and severe electrolyte depletion.

3. Recovery Phase (Weeks to Months)

• Resolution: Commences exclusively upon complete, absolute cessation of all cannabinoid products.
• Symptoms resolve over days to weeks; normal gastric motility, appetite, and body weight are restored. Compulsive bathing behavior vanishes.
• Recurrence Rule: If the patient resumes cannabis use—even weeks, months, or years later, and even in modest quantities—hyperemetic relapse is nearly 100% inevitable.

Differential Diagnostic Matrix

---

4. Emergency & Inpatient Management of Acute CHS

The emergency management of acute CHS requires specialized pharmacotherapy. The clinician must avoid standard medical routines that fail in this population.

The Failure of Conventional Antiemetics

Standard antiemetic agents routinely administered in emergency departments—including $5-\text{HT}_3$ serotonin receptor antagonists (ondansetron, granisetron), dopamine receptor antagonists (metoclopramide, prochlorperazine), and phenothiazines/antihistamines (promethazine)—are notoriously ineffective for CHS. These agents act on the chemoreceptor trigger zone and vagal afferents responsive to cytotoxic or motion-induced triggers, failing to correct the underlying enteric dysmotility and TRPV1 vanilloid desensitization driving CHS.

First-Line Acute Pharmacotherapies

1. Topical Capsaicin Cream (0.025% to 0.075%):
   • Mechanism: Capsaicin is an active alkaloid derived from chili peppers that serves as an ultra-potent direct agonist at TRPV1 vanilloid receptors. Topical application produces intense cutaneous sensory activation followed by rapid exhaustion and depletion of substance P from sensory nerve terminals. It pharmacologically mimics the heat of a scalding shower, reactivating hypothalamic and enteric TRPV1 signaling and terminating hyperemesis.
   • Application Protocol: Apply a thin layer of 0.025% to 0.075% capsaicin cream to the abdomen, epigastrium, or upper back. Symptoms typically abate within 30 to 45 minutes.
   • Clinical Precautions: The clinician and patient must wear nitrile gloves; strictly avoid contact with mucous membranes, eyes, or open skin; and warn the patient of intense cutaneous burning sensations.
2. First- and Second-Generation Antipsychotics:
   • Intravenous Haloperidol ($0.5\text{ to }2\text{ mg}$ IV): Highly effective in terminating refractory hyperemesis. Haloperidol acts as a potent central $D_2$ antagonist with prominent actions in the limbic system and medullary vomiting centers, reducing visceral hyperalgesia. Monitor baseline QTc interval.
   • Olanzapine ($2.5\text{ to }5\text{ mg}$ PO, sublingual, or IM): Exhibits broad-spectrum antagonism across $5-\text{HT}_2, 5-\text{HT}_3, D_2$, and $\alpha_1$ receptors, providing rapid antiemetic and sedative action.
3. Aggressive Intravenous Hydration & Electrolyte Repletion:
   • Administer 2 to 4 liters of isotonic crystalloids (Normal Saline or Lactated Ringer’s) to correct intravascular depletion, restore renal perfusion, and treat prerenal azotemia.
   • Aggressively replete potassium ($KCl$) and magnesium to resolve hypokalemic hypochloremic metabolic alkalosis and stabilize the cardiac membrane.
4. Adjunctive Benzodiazepines (Lorazepam $1\text{ to }2\text{ mg}$ IV): Provides valuable anxiolysis, reduces sympathetic arousal, and alleviates the severe anticipatory agitation associated with unrelenting vomiting.

Definitive Long-Term Management

The Advanced Practice Registered Nurse must clearly communicate to the patient that complete, permanent abstinence from all cannabinoids is the only curative intervention. Tapering, switching to edibles, using low-potency formulations, or substituting "pure CBD" will inevitably trigger recurrence. Motivational interviewing should be initiated once acute emesis has resolved.

---

5. Synthetic Cannabinoids & Novel Investigational Pharmacotherapies for CUD

Synthetic Cannabinoid Receptor Agonists (SCRAs: "Spice", "K2")

Synthetic cannabinoids are human-manufactured lipophilic compounds originally developed for scientific receptor research, illicitly sprayed onto inert plant material and marketed as "herbal incense":

• Pharmacological Differences from Natural Cannabis: Natural THC is a partial agonist at $CB_1$ receptors ($K_i \sim 40\text{ nM}$) that co-occurs with protective cannabidiol. Synthetic cannabinoids (e.g., JWH-018, AB-PINACA, MDMB-4en-PINACA) are full agonists at $CB_1$ receptors, exhibiting binding affinities 2 to 100 times greater than THC, with zero cannabidiol content.
• Severe Toxidrome: SCRAs do not produce gentle relaxation; they precipitate catastrophic clinical toxicity: florid delirium, acute psychosis with violent agitation, hyperthermia, unprovoked seizures, myocardial infarction (via coronary vasospasm), and acute tubular necrosis.
• Coagulopathy Warning: Multiple outbreaks of life-threatening hemorrhagic coagulopathy have occurred when illicit synthetic cannabinoid batches were adulterated with brodifacoum (a long-acting vitamin K-antagonist rodenticide), producing catastrophic mucosal bleeding, gross hematuria, and intracranial hemorrhage requiring massive doses of oral vitamin K1.
• Toxicology Limitations: SCRAs are structurally unrelated to phytocannabinoid metabolites and do not cross-react on routine hospital urine drug immunoassay screens. Confirmation requires specialized liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Investigational Pharmacotherapies for Cannabis Use Disorder

While no FDA-approved medications currently exist for CUD, several promising agents have emerged in high-quality clinical trials:

1. N-Acetylcysteine (NAC):
   • Mechanism: NAC is a prodrug to L-cysteine, which crosses the blood-brain barrier and fuels the cystine-glutamate antiporter (system $x_c^-$) in astrocytic glial cells. In chronic cannabis exposure, nucleus accumbens extrasynaptic glutamate levels are depleted. NAC upregulates system $x_c^-$, restoring basal extrasynaptic glutamate concentrations and dampening cue-induced drug-seeking behavior.
   • Clinical Evidence: In a landmark multi-site, randomized controlled trial (Gray et al.), NAC $1,200\text{ mg}$ PO twice daily combined with contingency management doubled the odds of achieving biochemically verified negative cannabis urine screens in adolescents and young adults (ages 15–21) compared to placebo.
2. Gabapentin:
   • Mechanism: Modulates the $\alpha_2\delta$ subunit of presynaptic P/Q-type voltage-gated calcium channels, suppressing excessive excitatory glutamate release in the amygdala.
   • Clinical Evidence: Mason et al. demonstrated that gabapentin ($1,200\text{ mg/day}$ administered as $300\text{ mg}$ morning, $300\text{ mg}$ midday, $600\text{ mg}$ bedtime) significantly reduced cannabis use, suppressed cravings, improved sleep latency, and restored cognitive executive function during acute cessation in adults with CUD.